Member Info for StockWatching

Due to the arbitration result, RKH will need additional equity for their Sea Lion share.

Any idea how much cash is staying in the sold US business?

Helium One Global Ltd (AIM:HE1) ("Helium One" or "the Company") announces that it has issued 1,341,463 ordinary shares in the Company to a service provider in lieu of cash payment.

Application will be made for the admission of the 1,341,463 new ordinary shares to trading on AIM ("Admission"). The Shares will rank pari passu with the existing ordinary shares and it is expected that Admission will become effective at 8.00 a.m. on 4 June 2025.

To much gas and not enough liquids in the well

Nickotine it was on L2 rsp offer. Now plenty of seller from 3.325

I told you party was over, Peel Hunt now has 500k seller at 3.5p.

I have been worried about the cash situation, but I think on the margin that the stock is now at a very interesting junction. If they only win one of these Phase II contract, it would be transformational for the revenue. Just one of these contract could double the annual revenue.

Party over after the so called "research" note, back to reality, poor assets in Morocco and Trinidad, bleeding money.

With the delay Navitas announced today for Sea Lion.

How is Sea Lion FID delay not bad news?

I think Sea Lion FID can continue to slip. Navitas problem is that the expected cash flow coming from the Shenandoah field is considerably lower with WTI around $61 vs $70-80 seen in 2024. Which means that they will have much less internal cash flow available for the Sea Lion development.

With the current oil price I think banks will be very reluctant to debt fund up to a $1bn of Sea Lion capex.

Which in turn is bad news for Borders.

Navitas Q1 update out today, Sea Lion FID delayed to H2 2025 from June. Which means it will take longer time to get a rig down for Borders & S.

Sounds like delays here, can only see a negaitve from that.

Nothing new here, talking to big pharma like they have done for the past years will the cash balance is depleting.

If they had sign new big contract it would be announced directly, anything else is wishful thinking.

The reality is that they have not announced ant Phase 3 clinical trials project since the January trading update.

The sensible thing is to raise and sort funding, if they want to build this business.

I think AGL few client will start to wonder if its so wise working with a corp lacking funding.

This is not a problem, many corp have done this where the placing is conditional on sorting that, not an issue at all. Only a formality.

To me it only feels like the share is being worked up for a equity raise, seen this movie so many times. 7p placing is my guess.